Livzon Pharmaceutical Group Inc. News

Pearl Group (000513): Performance is in line with expectations, diversified development of the main business

Sep 1 00:00

Pearl Group (000513): Performance is in line with expectations, BD is expected to accelerate

Aug 25 00:00

Pearl Group (000513): Stable operation awaiting transformation of BD and self-developed projects

Aug 24 13:26

Livingzhu Group (000513): Steady increase in revenue of sex promoting hormones accelerates R&D of differentiated innovation pipelines

Aug 23 16:31

Pearl Group (000513): Revenue is under pressure in the short term, and the research pipeline is abundant and continues to increase BD efforts

Aug 23 15:16

Pearl Group (000513): Performance is in line with expectations, BD is expected to accelerate

Aug 23 00:00

Pearl Group (000513): Steady performance, optimistic about long-term innovation and implementation

Apr 28 18:06

Dongwu Securities released a research report on April 26 stating that it gave the Pearl Group (000513.SZ) a buying rating. The main reasons for the rating include: 1) the gonadotropin and diagnostic reagent sector grasped the impressive growth rate of mar

Zhitong FinanceApr 26 19:46

Pearl Group (000513): Excellent performance in the field of promotion and diagnostic reagents, and steady overall profit

Apr 26 19:21

Pacific released a research report on April 9 stating that it gave the Pearl Group (000513.SZ) a buying rating. The main reasons for the rating include: 1) chemical preparations are under pressure, Chinese medicine formulations are growing; 2) reducing co

Zhitong FinanceApr 9 17:51

Pearl Group (000513): Performance is in line with expectations, innovative layout ushered in a harvest period

Apr 8 00:00

Lizhu Group (000513) Company Brief Review Report: Short-term Slowdown in Performance, Rapid Advancement of R&D

Apr 3 07:26

Pearl Group (000513): Performance is in line with expectations, the Chinese medicine sector is growing well

Apr 3 00:00

Pearl Group (000513) Company Information Update Report: Diversified layout stabilizes performance, innovative drugs and high-barrier formulations promote development

Apr 1 00:00

Pearl Group (000513): Chinese medicines and APIs drive performance improvement

Mar 31 00:00

Pearl Group (000513): Revenue and profit remained stable, and the API and Chinese medicine sector performed well

Mar 29 19:16

Pearl Group (000513): Innovation and transformation gradually realise potential big single products to help grow

Mar 7 00:00

Pearl Group (000513) Company's First Coverage Report: Innovative Drugs and High-Barrier Formulations Work Together to Promote Diversified Layout to Promote Development

Jan 24 18:26

Research Report Nuggets: Dongwu Securities: Livzon Group's main business is growing steadily, giving it the first “buy” rating

Gelonghui FinanceDec 19, 2023 17:34

Livzon Group (000513): Diversified main business, steady development of innovative microspheres and biopharmaceuticals, opening the second growth

Dec 19, 2023 07:42